Antibody to hepatitis E virus in HIV-infected individuals and AIDS patients. J Viral Hepat 1997; 4: 279–283. 10  Neukam K, Barreiro selleck screening library P, Macias J et al. Chronic hepatitis E in HIV patients: rapid progression to cirrhosis and response to oral ribavirin. Clin Infect Dis 2013; 57: 465–468. 11  Sagnelli E, Pisaturo M, Stanzione M et al.

Outcomes and response to therapy among patients with acute exacerbation of chronic hepatitis C. Clin Gastroenterol Hepatol 2013; epub ahead of print doi: 10.1016/j.cgh.2013.03.025. The following recommendations concern the management of patients with HBV/HIV or HCV/HIV who have developed end-stage liver disease (ESLD) and/or hepatocellular carcinoma (HCC). For the assessment and evaluation of evidence, the single priority question agreed was whether ultrasound scan (USS) surveillance testing

should be performed 6- or 12-monthly to detect early HCC in adults with chronic viral hepatitis/HIV infection. Outcomes Dabrafenib were ranked (critical, important and not important) by members of the Writing Group. The following were agreed as critical outcomes: HCC mortality, HCC missed diagnoses and cost of screening. Surveillance methods were compared where data were available and differences in outcome assessed. No study was identified that specifically examined chronic viral hepatitis in HIV infection. Recommendations and links to evidence for HBV monoinfection, including

management of HBV-related ESLD, have recently been published in NICE guidance [1]. Details of the search strategy and literature review are contained in Appendix 2. We recommend screening for and subsequent management of complications of cirrhosis and portal hypertension in accordance with national guidelines on the management of liver disease (1A). We recommend HCC screening with 6-monthly ultrasound (1A) and suggest 6-monthly serum alpha-fetoprotein (AFP) (2C) should be offered to all cirrhotic patients with HBV/HIV Staurosporine concentration and HCV/HIV infection. We recommend cirrhotic patients with chronic viral hepatitis and HIV infection should be managed jointly with hepatologists or gastroenterologists with knowledge of end-stage liver disease, preferably within a specialist coinfection clinic. We suggest all non-cirrhotic patients with HBV/HIV infection should be screened for HCC six monthly. We recommend all patients with hepatitis virus/HIV infection with cirrhosis should be referred early, and no later than after first decompensation, to be assessed for liver transplantation. We recommend eligibility for transplantation should be assessed at a transplant centre and in accordance with published guidelines for transplantation of HIV-infected individuals.